Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Elixia Central Florida LLC

Neither a doctor nor a teaching hospital

Research payments

$605,140

78 payments

Through program year 2025, Elixia Central Florida LLC is reported as receiving $605,140 in research payments, across 78 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $256,444 39
2024 Research $319,696 37
2023 Research $29,000 2

Breakdown

Who paid Research payments · program years 2023–2025
  1. Eli Lilly and Company $267,839 4 payments
  2. CSL Behring $109,310 48 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $84,051 20 payments
  4. Aurinia Pharma U.S., Inc. $75,715 5 payments
  5. Otsuka Pharmaceutical Development & Commercialization, Inc. $68,225 1 payment
Studies the money was for Research payments · program years 2023–2025
  1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $122,674 2 payments
  2. A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis $109,310 48 payments
  3. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 KG M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease $86,826 1 payment
  4. LUPKYNIS Registry Study $75,715 5 payments
  5. BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney $73,212 17 payments
  6. Epidemiology of Igan in the US and Its Associated Burden-Site-Based Census and Focus Phase $68,225 1 payment
  7. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 KG M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease $58,339 1 payment
  8. A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a $10,839 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record